Anika Therapeutics Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2012. For the period, the company expects total revenue in the range of $22.0 million to $23.0 million, compared with $18.4 million in the fourth quarter of 2011.

For the full year, the company expects total revenue to be in the range of $70.0 million and $71.6 million, compared with $64.8 million a year earlier. The company expects to equal or exceed its previously announced guidance of $0.74 net income per diluted share for full-year 2012.